Contents

ARTICLES

1423 Overlapping Drug Interaction Sites of Human Butyrylcholinesterase Dissected by Site-Directed Mutagenesis
Yael Loewenstein-Lichtenstein, David Glick, Nelly Gluzman, Meira Sternfeld, Haim Zakut, and Hermona Soreq

1432 Analysis of the α2C-Adrenergic Receptor Gene Promoter and Its Cell-Type-Specific Activity
Jean Sébastien Saulnier-Blache, Qing Yang, John D. Sherlock, and Stephen M. Lanier

1443 Activation of the Skeletal Muscle Ryanodine Receptor by Suramin and Suramin Analogs
Martin Hohenegger, Marina Matyash, Kati Poussu, Annegret Herrmann-Frank, Sandor Sarközi, Frank Lehmann-Horn, and Michael Freissmuth

1454 Basis for the Loss of Aryl Hydrocarbon Receptor Gene Expression in Clones of a Mouse Hepatoma Cell Line
Jianzhong Zhang, A. John Watson, Markus R. Probst, Elaine Minehart, and Oliver Hankinson

1463 Drug Sensitivity and Sequence Specificity of Human Recombinant DNA Topoisomerases IIα (p170) and IIβ (p180)
Mariagrazia Cornarotti, Stella Tinelli, Elaine Willmore, Franco Zunino, L. Mark Fisher, Caroline A. Austin, and Giovanni Capranico

1472 Acquired Camptothecin Resistance of Human Breast Cancer MCF-7/C4 Cells with Normal Topoisomerase I and Elevated DNA Repair
Akira Fujimori, Malini Gupta, Yuko Hoki, and Yves Pommier

Continued
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1479</td>
<td>Inverse Agonist-Induced Up-Regulation of the Human $\beta_2$-Adrenoceptor in Transfected Neuroblastoma X Glioma Hybrid Cells</td>
<td>David J. MacEwan and Graeme Milligan</td>
</tr>
<tr>
<td>1487</td>
<td>Enhanced Biological Activity of Antisense Oligonucleotides Complexed with Glycosylated Poly-L-lysine</td>
<td>A. J. Stewart, C. Pichon, L. Meunier, P. Midoux, M. Monsigny, and A. C. Roche</td>
</tr>
<tr>
<td>1495</td>
<td>Inhibition of Capacitative Ca$^{2+}$ Entry into Cells by Farnesylcysteine Analogs</td>
<td>Yajun Xu, Bryant A. Gilbert, Robert R. Rando, Longchuan Chen, and Armen H. Tashjian, Jr.</td>
</tr>
<tr>
<td>1502</td>
<td>Identification of Enzymes Catalyzing Two-Step Phosphorylation of Cidofovir and the Effect of Cytomegalovirus Infection on Their Activities in Host Cells</td>
<td>Tomas Cihlar and Ming S. Chen</td>
</tr>
<tr>
<td>1511</td>
<td>Transgenic Mice with High Levels of Superoxide Dismutase Activity are Protected from the Neurotoxic Effects of 2'-NH$_2$-MPTP on Serotonergic and Noradrenergic Nerve Terminals</td>
<td>Anne M. Andrews, Bruce Ladenheim, Charles J. Epstein, Jean Lud Cadet, and Dennis L. Murphy</td>
</tr>
<tr>
<td>1520</td>
<td>Effects of Volatile Anesthetics on the G Protein-Regulated Muscarinic Potassium Channel</td>
<td>Janos Magyar and Gabor Szabo</td>
</tr>
<tr>
<td>1529</td>
<td>Transport of Adenosine by Recombinant Purine- and Pyrimidine-Selective Sodium/Nucleoside Cotransporters from Rat Jejunum Expressed in Xenopus laevis Oocytes</td>
<td>Sylvia Y. M. Yao, Amy M. L. Ng, Mabel W. L. Ritzel, Wendy P. Gati, Carol E. Cass, and James D. Young</td>
</tr>
<tr>
<td>1541</td>
<td>Subtype-Selective Inhibition of N-Methyl-d-aspartate Receptors by Haloperidol</td>
<td>V. I. Ilyin, E. R. Whittemore, J. Guastella, E. Weber, and R. M. Woodward</td>
</tr>
<tr>
<td>1567</td>
<td>Alniditan, a New 5-Hydroxytryptamine$<em>{1D}$ Agonist and Migraine-Abortive Agent: Ligand-Binding Properties of Human 5-Hydroxytryptamine$</em>{1Da}$, Human 5-Hydroxytryptamine$<em>{1DB}$, and Calf 5-Hydroxytryptamine$</em>{1D}$ Receptors Investigated with [3H]5-Hydroxytryptamine and [3H]Alniditan</td>
<td>José E. Leysen, Walter Gommeren, Lieve Heylen, Walter H. M. L. Luyten, Inez Van De Weyer, Peter Vanhonenacker, Guy Haegeman, Alain Schotte, Paul Van Gompel, Ria Wouters, and Anne S. Lesage</td>
</tr>
</tbody>
</table>

Continued
CONTENTS (cont'd)

1581 Enantioselectivity of Steroid-Induced γ-Aminobutyric Acid$_{A}$ Receptor Modulation and Anesthesia

Lisa L. Wittmer, Yuefei Hu, Melissa Kalkbrenner, Alex S. Evers, Charles F. Zorumski, and Douglas F. Covey

1587 Reconstitution of Recombinant Bovine A$_1$ Adenosine Receptors in Sf9 Cell Membranes with Recombinant G Proteins of Defined Composition

Robert A. Figler, Stephen G. Graber, Margaret A. Lindorfer, Hiroshi Yasuda, Joel Linden, and James C. Garrison

1596 Properties of the Pituitary Adenylate Cyclase-Activating Polypeptide I and II Receptors, Vasoactive Intestinal Peptide$_1$, and Chimeric Amino-Terminal Pituitary Adenylate Cyclase-Activating Polypeptide/Vasoactive Intestinal Peptide$_1$ Receptors: Evidence for Multiple Receptor States

Jean Van Rampelbergh, Philippe Gourlet, Philippe De Neef, Patrick Robberecht, and Magali Waelbroeck

1605 Relative Contribution of Polar Interactions and Conformational Compatibility to the Binding of Neurokinin-1 Receptor Binding Antagonist

Tung Ming Fong, Hong Yu, Ruey-Ruey C. Huang, Margaret A. Cascieri, and Christopher J. Swain

1612 Acid-Catalyzed Oxidation of the Anticancer Agent Mitoxantrone by Nitrite Ions

Krzysztof J. Reszka and Colin F. Chignell

1619 The Third Extracellular Loop of the Human δ-Opioid Receptor Determines the Selectivity of δ-Opioid Agonists


1625 Evidence for an Internal Phenylalkylamine Action on the Voltage-Gated Potassium Channel Kv1.3

Heiko Rauer and Stephan Grissmer

1635 Site-Directed Mutagenesis of the Human A$_1$ Adenosine Receptor: Influences of Acidic and Hydroxy Residues in the First Four Transmembrane Domains on Ligand Binding

Hemang Barbhaiya, Rebecca McClain, Adriaan IJzerman, and Scott A. Rivkees

1643 The Role of Inactivation in Open-Channel Block of the Sodium Channel: Studies with Inactivation-Deficient Mutant Channels

Augustus O. Grant, J. Edward John, Vladislav V. Nesterenko, C. Frank Starmer, and J. Randall Moorman

1651 Inverse Agonistic Effect of ICI-174,864 on the Cloned δ-Opioid Receptor: Role of G Protein and Adenylyl Cyclase Activation

Tillie T. Chiu, Lisa Y. Yung, and Yung H. Wong

Continued
Contents (cont'd)

1658 Identification and Pharmacological Characterization of [125I]L-750,667, a Novel Radioligand for the Dopamine D4 Receptor

1665 Evans Blue Antagonizes Both α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate and Kainate Receptors and Modulates Receptor Desensitization
Christopher J. Price and Lynn A. Raymond

Accelerated Communications

1672 Novel Nonpeptide Agents Potently Block the C-Type Inactivated Conformation of Kv1.3 and Suppress T Cell Activation
Angela Nguyen, John C. Kath, Douglas C. Hanson, Michael S. Biggers, Paul C. Canniff, Carol B. Donovan, Robert J. Mather, Mathew J. Bruns, Heiko Rauer, Jayashree Aiyar, Albrecht Lepple-Wienhues, George A. Gutman, Stephan Grissmer, Michael D. Cahalan, and K. George Chandy

1680 Calcium-Dependent Inactivation of Recombinant N-Methyl-D-Aspartate receptors Is NR2 Subunit Specific
Johannes J. Krupp, Bryce Vissel, Stephen F. Heinemann, and Gary L. Westbrook

1689 Author Index to Volume 50
1700 Subject Index to Volume 50

Visit Molecular Pharmacology on the World-Wide Web at:
http://www.wwilkins.com/molec_pharm/

About the cover: Targeting of δ-opioid receptor to surface membranes. COS-1 cells were transfected with a mouse δ-opioid receptor mutant (D128A), for which the conserved aspartate in the third membrane domain is replaced by alanine. Cells were double-labeled with fluorescein-conjugated concanavalin A to label the plasma membrane (green) and with an anti-δ-opioid receptor antibody followed by rhodamine-conjugated streptavidin (red). Yellow shows the region of colocalization. This mutant exhibited reduced expression and subtle changes in its ability to bind certain agonist ligands. From Befort, K., L. Tabbara, S. Bausch, C. Chavkin, C. Evans, and B. Kieffer. The conserved aspartate residue in the third putative transmembrane domain of the δ-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. Mol. Pharmacol. 49: 216–223 (1996).